- Trials with a EudraCT protocol (14,142)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
14,142 result(s) found for: Period.
Displaying page 7 of 708.
EudraCT Number: 2015-003538-28 | Sponsor Protocol Number: CIGE025AIA05 | Start Date*: 2016-02-16 |
Sponsor Name:Novartis Pharmaceuticals | ||
Full Title: A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years)... | ||
Medical condition: Moderate-severe inadequately controlled Allergic Asthma | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-004382-25 | Sponsor Protocol Number: N01363 | Start Date*: 2015-02-24 | |||||||||||
Sponsor Name:UCB Japan Co. Ltd. | |||||||||||||
Full Title: An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Levetiracetam in Japanese Patients (≥4 to <16 Years) With Uncontrolled Generalized Toni... | |||||||||||||
Medical condition: - Epilepsy - Generalized Tonic-clonic Seizures | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001040-11 | Sponsor Protocol Number: ACN-PRT-AD-12-1 | Start Date*: 2015-04-13 | |||||||||||
Sponsor Name:Astellas Pharma China, Inc. | |||||||||||||
Full Title: A Multicentre, Open-Label, Randomized, Controlled Study of Long-Term Intermittent Maintain Treatment with 0.03% Tacrolimus Ointment in Pediatric Patient with Moderate to Severe Atopic Dermatitis | |||||||||||||
Medical condition: Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001096-43 | Sponsor Protocol Number: PHRN14-AM/PERFORMUS | Start Date*: 2015-07-10 | |||||||||||
Sponsor Name:CHRU de Tours | |||||||||||||
Full Title: Treatment of superficial voluminous complicated slow-flow vascular malformations with sirolimus: a phase 2 trial in children observational-phase designed | |||||||||||||
Medical condition: vascular malformations | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002374-39 | Sponsor Protocol Number: I8B-MC-ITSI | Start Date*: 2017-12-27 | |||||||||||
Sponsor Name:Lilly S.A. | |||||||||||||
Full Title: Protocol I8B-MC-ITSI A Prospective, Randomized, Double-Blind, Crossover Comparison Evaluating Compatibility and Safety of LY900014 and Insulin Lispro with an External Continuous Subcutaneous Insuli... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000605-24 | Sponsor Protocol Number: CSL312_2001 | Start Date*: 2018-12-20 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: A multicenter, randomized, placebo-controlled, parallel-arm study to investigate the efficacy, pharmacokinetics, and safety of CSL312 in subjects with hereditary angioedema | |||||||||||||
Medical condition: Hereditary angioedema | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001606-14 | Sponsor Protocol Number: 2017/2555 | Start Date*: 2017-10-10 | ||||||||||||||||
Sponsor Name:Gustave Roussy | ||||||||||||||||||
Full Title: A study of patient preference between ODM-201 and Enzalutamide in men with metastatic castrate-resistant prostate cancer | ||||||||||||||||||
Medical condition: Metastatic Castration resistant prostate cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002718-17 | Sponsor Protocol Number: IMVT-1401-2401 | Start Date*: 2023-06-19 | |||||||||||
Sponsor Name:Immunovant Sciences, GmbH | |||||||||||||
Full Title: A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | |||||||||||||
Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002240-17 | Sponsor Protocol Number: ATR-101-301 | Start Date*: 2017-05-16 | |||||||||||
Sponsor Name:Millendo Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome | |||||||||||||
Medical condition: endogenous Cushing’s syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001866-39 | Sponsor Protocol Number: NOE-TGN-201 | Start Date*: 2022-02-24 | |||||||||||
Sponsor Name:Noema Pharma | |||||||||||||
Full Title: A Phase II/III, multicentre, 8-week run-in phase followed by a 12- week, prospective, parallel-group, double-blind, randomized withdrawal, placebo-controlled study, with a 52 week open label exten... | |||||||||||||
Medical condition: Trigeminal neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002432-17 | Sponsor Protocol Number: ALN-AS1-003 | Start Date*: 2017-11-22 | ||||||||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: ENVISION: A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porph... | ||||||||||||||||||
Medical condition: Acute Hepatic Porphyrias (AHP) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) DK (Completed) CZ (Completed) SE (Completed) BG (Completed) FI (Completed) BE (Completed) FR (Completed) PL (Completed) NL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003278-42 | Sponsor Protocol Number: TV48125-CNS-30056 | Start Date*: 2017-07-10 |
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | ||
Full Title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of T... | ||
Medical condition: Episodic Cluster headache (ECH) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) NL (Completed) PL (Prematurely Ended) FI (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-004300-36 | Sponsor Protocol Number: acmed 01 | Start Date*: 2006-02-27 |
Sponsor Name:Plymouth Hospital NHS Trust, R&D dept | ||
Full Title: Use of somatostatin analogue therapy as primary medical treatment of acromegaly | ||
Medical condition: Acromegaly | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003534-27 | Sponsor Protocol Number: CIGE025B1301 | Start Date*: 2016-02-16 |
Sponsor Name:Novartis Pharmaceuticals | ||
Full Title: A 24 Week, Open Label, Multi-center Evaluation of Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic ... | ||
Medical condition: Allergic asthma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2006-001011-29 | Sponsor Protocol Number: ML20247 | Start Date*: 2006-12-14 |
Sponsor Name:Roche (Hellas) S.A. | ||
Full Title: A phase II study to assess the efficacy of intravenous loading doses of Bondronat 6 mg on metastatic bone pain in patients with breast cancer and skeletal metastases | ||
Medical condition: Metastatic bone disease related metastatic bone pain with breast as the primary site. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005448-87 | Sponsor Protocol Number: B1801315 | Start Date*: 2012-05-14 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S) COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002640-25 | Sponsor Protocol Number: 217-MDD-302 | Start Date*: 2019-12-09 | |||||||||||
Sponsor Name:Sage Therapeutics, Inc. | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DIS... | |||||||||||||
Medical condition: MAJOR DEPRESSIVE DISORDER | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001685-87 | Sponsor Protocol Number: M516102-EU03 | Start Date*: 2008-08-28 |
Sponsor Name:Maruho Co., Ltd | ||
Full Title: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTRE PHASE IIB DOSE-FINDING STUDY OF M516102 IN THE TREATMENT OF PRURITUS ASSOCIATED WITH ATOPIC DERMATITIS. | ||
Medical condition: Pruritus associated with Atopic dermititis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) CZ (Completed) BE (Completed) GB (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005006-66 | Sponsor Protocol Number: 2013118 | Start Date*: 2014-01-21 |
Sponsor Name:Procter and Gamble | ||
Full Title: A 2-arm, randomised, single - (Investigator) blind, controlled, parallel design study in common cold sufferers experiencing nasal congestion to assess the speed of action of Vicks® VapoRub® (VVR) | ||
Medical condition: Nasal congestion due to common cold in adults | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004864-24 | Sponsor Protocol Number: COPD-1 | Start Date*: 2013-07-09 |
Sponsor Name:Bionorica SE | ||
Full Title: Randomized, placebo-controlled, double-blind, cross-over trial with Bronchipret and Sinupret to evaluate acceleration of mucociliary clearance (MCC) | ||
Medical condition: PR1: Acceleration of mucociliary clearance as a therapeutic effect when treating inflammation of the nasal sinuses PR2: Acceleration of mucociliary clearance as a therapeutic effect when treating ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
